UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 12, 2002
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
State or other jurisdiction of incorporation: Delaware
Commission File No.: 333-45241
I.R.S. Employer Identification No.: 22-3542636
Address of principal executive offices 165 Ludlow Avenue
Northvale, New Jersey 07647
Registrant's telephone number, including area code: 201 750-2646
ITEM 5. OTHER EVENTS
(a) EXPANSION OF BOARD OF DIRECTORS; ELECTION OF NEW DIRECTORS
Elite has expanded its Board of Directors from four to seven, and has elected
John P. deNuefville, Richard A. Brown and John A. Moore to fill the new
positions. The press release issued December 18, 2002 by Elite Pharmaceuticals,
Inc. regarding such appointment is attached hereto as Exhibit 99.1 and is
incorporated herein.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
99.1 Press Release of Elite Pharmaceuticals, Inc., dated
December 18, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: December 18, 2002 ELITE PHARMACEUTICALS, INC.
By: /s/ Atul M. Mehta
-----------------------------
Atul M. Mehta
President
-2-